BNET Industries

Market Cap:$245.1M
Last Fiscal Year Sales:$3.1M
  • Public
  • US
Dow Jones Description

BioMimetic Therapeutics, Inc. develops and commercializes innovative products to help stimulate the bodys natural tissue regenerative process. We believe our protein therapeutic-device combination products have the potential to significantly improve the treatment of musculoskeletal injuries and conditions affecting bones, tendons, ligaments and cartilage. Our platform regenerative technology, which incorporates a potent version of one of the bodys natural key stimulators of tissue repair, may offer physicians advanced biological solutions to actively stimulate tissue healing and regeneration. We have already demonstrated that this technology is safe and effective in stimulating bone and periodontal regeneration in the jaws with the U.S. and Canadian regulatory approvals of our first product, GEM 21S ® Growth-factor Enhanced Matrix. With the divestiture of GEM 21S in January 2008, we are now focused on developing this technology to stimulate tissue healing in orthopedic applications (such as distal radius, or wrist, fractures and fusions of the bones in the foot and ankle to eliminate chronic pain from trauma or arthritis), and potentially spine and sports injury applications. Our current product candidates use the same key stimulator as GEM 21S , and are designed to target a broad range of clinical indications in bone, cartilage, ligament and tendon repair. ...

President, Chief Executive Officer and Director
Samuel Lynch
Number of Employees 88
Contact Information

389-A Nichol Mill Lane

Franklin, Tennessee 37067

biomimetics.com

(615) 844-1280

NAICS Code Surgical and Medical Instrument Manufacturing: 339112

Recent Events

  • EU Panel: Affirm Benefits Of Celvapan, Focetria, Pandemrix

    11/20/09 - Bond / Stock Rating - View Story

  • BioMimetic narrows losses in 3Q

    11/06/09 - Financial Announcement - View Story

  • Canaccord Adams Reiterates a 'Buy' Rating on BioMimetic Therapeutics BMTI; Raises PT

    10/14/09 - Bond / Stock Rating - View Story

  • BioMimetic narrows loss in 2Q

    8/10/09 - Financial Announcement - View Story

News & Analysis

biomimetic therapeutics inc. - All News and Analysis

Decision Makers

Name (plus bio) Position
Samuel Lynch President, Chief Executive Officer and Director
Charles Hart Vice President & Chief Scientific Officer
Edward Hart Charles Chief Scientific Officer &Vice President
Larry Bullock Chief Financial Officer
Steven Hirsch Coo & Executive Vice President
Thorkil K. Christensen Chief Financial Officer of Novo A, S
Thorkill K. Christensen Chief Financial Officer of Novo A, S
Leo Snel Senior Vice President of R&D Protein Biochemistry
Mark Citron Senior Vice President, Regulatory Affairs & Quality Systems
Hans Kestler Vice President, Sports Medicine
James Monsor Vice President, Operations
John McKay Vice President, Quality, Environ, Health & Safety
Russ Pagano Vice President of Regulatory and Clinical Affairs
William Beasley Vice President, Clinical Research
Alexander Vaccaro Director of the Delaware Valley Regional Spinal Cord Injury Center
Arnold Caplan Director of Skeletal Research Center and Professor of Biology, Case Western Reserve University
Kearstin Patterson Assoc Director, Corp Comm
Rafe Donahue Assoc Director, Statistics
Earl Douglas General Counsel
Ed Akelman Professor
Jeffrey Hollinger Professor of Biological Sciences
Joseph Lane Professor of Orthopedic Surgery
Kevin Foley Professor of Neurosurgery, University of Tennessee
Myron Nevins Associate Clinical Professor of Periodontology

Board of Directors

Name (plus bio) Position
Charles W. Federico Director, Chair Compensation Committee
Doug Watson Director, Chair Nominating and Governance Committee
James G. Murphy Director, Chair Audit Committee
James G. Murphy Director, Chair Audit Committee
Larry Papasan Director and Chairman
Gary E. Friedlaender Chairman of Biomimetic's Orthopedic Sab
Jim Murphy Chair
Michael Ehrlich Professor and Chairman, Department of Orthopedics
Alex Vaccaro Board of Directors
Christopher Ehrlich Member of Biomimetic's Board of Directors
Douglas G. Watson Board of Directors
John Mathis Board of Directors
Robert Genco Board of Directors
Sheldon Lin Board of Directors
Stuart Goodman Board of Directors
William Giannobile Board of Directors

Samuel E. Lynch, D.M.D., D.M.Sc. is founder, President, Chief Executive Officer of BioMimetic. Dr. Lynch also served as Chairman of our board of directors from company inception in 1999 until August 2005. He has spent his career in health care management, product development, and earlier in academic medicine/dentistry, including research and patient care. He received his Doctorate of Medical Sciences and Specialty in Periodontology from the Harvard Medical and Dental Schools respectively as well as a Doctorate of Dental Medicine from Southern Illinois University School of Dental Medicine. He has published and lectured extensively worldwide and is a co-inventor of BioMimetic's technologies. In this era of complex regulatory environments he is one of only a handful of doctors to have been fortunate enough to make a breakthrough discovery and oversee its development through all phases of product development culminating in FDA approval and commercialization. Dr. Lynch is also a member of the board of directors of GreenBankshares, Inc. and numerous non-profit organizations.

Organization Position Status
BioMimetic Therapeutics, Inc. President, Chief Executive Officer and Director Current
BioMimetic Therapeutics, Inc. Board of Directors Current
BioMimetic Therapeutics, Inc. Founder, President, Chief Executive Officer Former
Osteohealth Vice President Former
Luitpold Pharmaceuticals, Inc. Vice President Former
Luitpold Pharmaceuticals, Inc. Executive Director Former
Harvard School of Dental Medicine Faculty Former
Harvard University Former
Harvard Medical School Doctorate Former

Organization Position Status
BioMimetic Therapeutics, Inc. Vice President & Chief Scientific Officer Current
Trf Pacific Commercial Real Estate Brokers Current
ZymoGenetics, Inc. Director of Corporate Communications Former
University of Washington Assistant Former
University of Washington Ph.D. Former
Oregon State University M.S. Former
University of California, Davis B.S. Former

Organization Position Status
BioMimetic Therapeutics, Inc. Chief Scientific Officer &Vice President Current

Larry Bullock joined BioMimetic in January 2004 as Chief Financial Officer. From January 1996 to February 2003, Mr. Bullock served as Chief Financial Officer of Ribozyme Pharmaceuticals Inc., now called Sirna Pharmaceuticals Inc., and as Chief Financial Officer of La Jolla Pharmaceuticals for five years prior to joining Sirna. He led both companies through their private to public transitions, completing private and initial public offerings and building the public reporting team. Mr. Bullock received his M.B.A. from the University of Utah and his B.A. from Indiana University.

Organization Position Status
BioMimetic Therapeutics, Inc. Chief Financial Officer Current
Ribozyme Pharmaceuticals Inc Chief Financial Officer Former
La Jolla Pharmaceutical Company Chief Financial Officer Former
University of Utah M.B.A. Former
Indiana University B.A. Former

Steve Hirsch joined BioMimetic in July 2005 as Executive Vice President, Orthopedics and Chief Operating Officer. From October 1996 to June 2005, Mr. Hirsch served in various positions in the Orthopedics Division of London-based Smith & Nephew, plc. His responsibilities at Smith & Nephew included responsibilities in the marketing and sales areas. From January 2003 to February 2005, Mr. Hirsch was the Senior Vice President and General Manager of the Reconstructive (total joint) Division of the orthopedics business. His last position with Smith & Nephew was President of the European Orthopedic business, with annual revenues in excess of $200 million. Mr. Hirsch spent 24 years in the orthopedic device industry, first with the Howmedica Division of Pfizer, Inc. where he held a variety of positions including Vice President of Sales and Marketing for the US Orthopedics business. Mr. Hirsch received a B.E.Sc. from the Johns Hopkins University and a M.S.I.A. from the Krannert School of Business at Purdue University.

Organization Position Status
BioMimetic Therapeutics, Inc. Coo & Executive Vice President Current
Smith & Nephew plc Former
Pfizer Inc. Former
Purdue University M.S. Former
The Johns Hopkins University B.E.Sc. Former

Thorkil K. Christensen , age 61, currently serves as the Chief Financial Officer of Novo A/S, where he has served in that position since 2003. From 1989 to 2003, he served in various positions at Novo Nordisk A/S, including Managing Director of Health Care Asia, Vice President of International Operations and Chief Executive Officer of China Operations. Mr. Christensen also currently serves on the boards of Nordic Institute of Asian Studies and Executives Global Network A/S, and as Vice Chairman of the Danish Chinese Business Forum.

Organization Position Status
BioMimetic Therapeutics, Inc. Chief Financial Officer of Novo A, S Current
BioMimetic Therapeutics, Inc. Board of Directors Current

Thorkil K. Christensen , age 61, currently serves as the Chief Financial Officer of Novo A/S, where he has served in that position since 2003. From 1989 to 2003, he served in various positions at Novo Nordisk A/S, including Managing Director of Health Care Asia, Vice President of International Operations and Chief Executive Officer of China Operations. Mr. Christensen also currently serves on the boards of Nordic Institute of Asian Studies and Executives Global Network A/S, and as Vice Chairman of the Danish Chinese Business Forum.

Organization Position Status
BioMimetic Therapeutics, Inc. Chief Financial Officer of Novo A, S Current
BioMimetic Therapeutics, Inc. Board of Directors Current

Leo Snel joined BioMimetic in August 2007 and is Senior Vice President of R&D Protein Biochemistry. He brings 30 years of protein science and product development expertise to BMTI, most recently at Amgen leading a Global Operations team to launch Amgen's first oncology protein therapeutic, Vectibix. Mr. Snel also led the CMC section filing of the BLA (Biologics License Application) and PLA (Production Facility License Application) for Vectibix, an antibody to treat late stage colorectal cancer. Prior to that, Mr. Snel spent two years at ZymoGenetics as Senior Director of Analytical Sciences and Contract Manufacturing, and 24 years at NovoNordisk where he held a variety of positions, including 6 years as Director of Biologics Development for the Health Care Division and was involved in regulatory filings worldwide involving recombinant insulins, liquid formulation of growth hormones (hGH Simplexx) and blood factor VII (NovoSevenn). He received his MSc from the Technical University of Denmark and a Diploma in Drug & Device Development from the Scandinavian International Management Institute.

Organization Position Status
BioMimetic Therapeutics, Inc. Senior Vice President of R&D Protein Biochemistry Current
Bmti Current
BioMimetic Therapeutics, Inc. Vice President, R & D Former
Novo Nordisk, Inc. Senior Director of Analytical Sciences and Contract Manufacturing Former
ZymoGenetics, Inc. Senior Director of Analytical Sciences and Contract Manufacturing Former
Analytical Sciences Board of Directors Former
Contract Manufacturing Board of Directors Former

Organization Position Status
BioMimetic Therapeutics, Inc. Senior Vice President, Regulatory Affairs & Quality Systems Current
Aigisrx Vice President, Regulatory Affairs and Quality Systems Current
Tyrx Pharma Inc Vice President Clinical and Regulatory Affairs Current
Genzyme Corporation Vice President of Quality Systems Former
BioMimetic Therapeutics, Inc. Vice President, Regulatory Affairs and Quality Systems Former
Osteotech, Inc. Senior Director of Scientific Affairs Former
ConvaTec Ltd. Director of Regulatory Affairs Former
BioMimetic Therapeutics, Inc. Corporate Officer Former
Bristol-Myers Squibb Company Former
Johnson & Johnson Former
Wagner College MS In Microbiology and Health Sciences Former

Hans Kestler joined BioMimetic in 2006 and is vice president, sports medicine. Previously, Mr. Kestler was director of orofacial healthcare and was responsible for both product and business development in support of the Company's first approved product, GEM 21S. Since successfully leading the divestiture of the Orofacial business to Luitpold Pharmaceuticals in early 2008, Mr. Kestler leads a focused team of research scientists pursuing the use of rhPDGF-BB in cartilage, tendon and ligament applications. Mr. Kestler's prior management experience includes leadership responsibilities in marketing, sales and product development in several medical device/tissue engineering therapeutic areas.

Organization Position Status
BioMimetic Therapeutics, Inc. Vice President, Sports Medicine Current

James Monsor is Vice President, Operations. Mr. Monsor spent 15 years in positions of increasing responsibility at Abbott Laboratories within operations and quality. Most recently, he was Director of Product Supply for ALK-Abello, where he was responsible for the entire product supply chain for US operations. He has had responsibility for all aspects of supply chain management, quality assurance, quality control, regulatory affairs, customer service, facilities management, construction management, and HR. His experience includes Aseptic Processing, Medical Devices, and Bulk Pharmaceuticals.

Organization Position Status
BioMimetic Therapeutics, Inc. Vice President, Operations Current
Alk-Abello Director of Product Supply Former
Abbott Laboratories Former
H&R, Inc. Former
University of California, Irvine B.S. Former

John McKay joined the Company effective September 28, 2007 and holds the position of Vice President, Quality and Environmental, Health, Safety (EHS). Mr. McKay brings 22+ years of international experience in the fields of Quality, EHS, Operations, Engineering, Compliance, Training, Integrated Auditing, Maintenance/Reliability and Product Development programs to BMTI. Most recently he served as Senior Director, Compliance at Stryker Physiotherapy Associates where he led the systems for healthcare quality, compliance and Corporate Integrity Agreement, and assured compliance with regulatory, ethics, code of conduct and company policies. Prior to that, he held several senior management positions within the Bayer Corporation, including Manager, Operational Excellence, leading global efforts for performance improvement, ISO standards, quality, management systems, and integrated auditing. He also spent 15 years at Lyondell, ARCO Chemical Company, Rohm and Haas Company where he held various global management positions in Manufacturing Excellence, Operational Excellence, Quality Assurance, Quality Control, EHS, Operations, Product Development, Engineering, Training, Supply Chain Management, Plant Management, Maintenance/Reliability, and Integrated Auditing. Mr. McKay received his B.S. in Chemical Engineering from Pennsylvania State University and is a graduate of the University of Pennsylvania Business School's Wharton Management Program. Mr. McKay holds several Quality, Environmental and Safety/Health certifications. His experience includes Pharmaceuticals, Medical Devices, Specialty/Intermediate Chemicals, Petrochemicals, and Contract Manufacturing.

Organization Position Status
BioMimetic Therapeutics, Inc. Vice President, Quality, Environ, Health & Safety Current
ARCO Chemical Company Former
The Pennsylvania State University B.S. In Chemical Engineering Former

Russ Pagano, Ph.D. joined the Company effective May 23, 2007 in the position of vice president of regulatory and clinical affairs. Dr. Pagano received his Ph.D. from Duke University and joined the US Food and Drug Administration ("FDA") as a scientific reviewer in the Office of Device Evaluation in 1994. He served as FDA chief of the Restorative Devices Branch, which included a portion of the organization's orthopedic products from 1997 to 2000. While leading this branch, he reviewed bone void fillers (BVF)and bone morphogenic protein (BMP)products from companies such as Medtronic and Stryker. He also held the position of FDA chief of the Pacing, Defibrillators and Leads Branch from October 2000 to May 2001. Since that time, he has been executive vice president and regulatory advisor at M Squared Associates, a consulting firm in Washington D.C. In that capacity, Dr. Pagano served as a regulatory consultant to BioMimetic and numerous other companies and helped prepare PMAs for filing and provided panel preparation services.

Organization Position Status
M Squared Associates, Inc Executive Vice President Current
BioMimetic Therapeutics, Inc. Vice President of Regulatory and Clinical Affairs Current
M Squared Associates, Inc Regulatory Advisor Current
Defibrillators Chief of the Restorative Devices Branch Former
Duke University Ph.D. Former

William Beasley is Vice President, Clinical Research. He previously served five years in clinical trials management at Covance, Inc., a large, multinational Clinical Research Organization (CRO) where he directed phase I - phase III clinical trials for major international pharmaceutical companies. In his current position, Mr. Beasley successfully conducted the pivotal trial on GEM 21S and has lead the Company's ongoing orthopedic clinical research program. He has implemented an electronic data capture (EDC) instrument developed by a small CRO into the company's clinical program, substantially improving clinical trial efficiencies. Mr. Beasley's clinical research management experience includes a diverse range of pharmaceuticals, biologics, medical devices and combination products in multiple therapy areas.

Organization Position Status
BioMimetic Therapeutics, Inc. Vice President, Clinical Research Current
BioMimetic Therapeutics, Inc. Board of Directors Current
BioMimetic Therapeutics, Inc. Director, Clinical Affairs Former
Edc Former
Covance, Inc. Former
The University of Tennessee B.S. Former

Organization Position Status
BioMimetic Therapeutics, Inc. Director of the Delaware Valley Regional Spinal Cord Injury Center Current

Organization Position Status
BioMimetic Therapeutics, Inc. Director of Skeletal Research Center and Professor of Biology, Case Western Reserve University Current
BioMimetic Therapeutics, Inc. Board of Directors Current
Illinois Institute of Technology B.S. in chemistry Former

Mr. Federico joined the BioMimetic board of directors in June of 2007. Mr. Federico currently serves as a director of Orthofix International N.V., where he also served as president from 1996 to 2001, and as president and chief executive officer from 2001 to 2006. From 1985 to 1996, Mr. Federico was general manager then president of Smith & Nephew Endoscopy (formerly Dyonics, Inc.). From 1981 to 1985, Mr. Federico served as vice president of Dyonics, initially as director of marketing and subsequently as general manager. Previously, he held management and marketing positions with General Foods Corporation, Air Products Corporation, Puritan Bennett Corporation and LSE Corporation. Mr. Federico also currently serves on the boards of SRI/Surgical Express, Inc., SaluMedica, LLC and Mako Surgical Corp.

Organization Position Status
BioMimetic Therapeutics, Inc. Director, Chair Compensation Committee Current
SRI/Surgical Express, Inc. Chairman of the Board Current
MAKO Surgical Corp. Board of Directors Current
Salumedica, LLC Board of Directors Current
Alveolus Incorporated Director Current
Orthofix International N.V. Director Current
BioMimetic Therapeutics, Inc. Board of Directors Current
Orthofix Inc. Director Current
Orthofix International N.V. Chief Executive Officer Former
Orthofix International N.V. President Former
Orthofix Inc. President Former
Puritan Bennett Former
American Sports Medicine Institute Board Member Former
Fordham University B.S. In Marketing Former
SRI/Surgical Express, Inc. Board of Directors Current

Douglas Watson has been a director since 1999. Mr. Watson s career spanned 33 years with Geigy/Ciba-Geigy/Novartis, in a variety of positions, including President of Ciba Pharmaceuticals Division from April 1986 to March 1996, President and Chief Executive Officer of Ciba-Geigy Corporation from April to December 1996, and President and Chief Executive Officer of Novartis Corporation, the U.S. subsidiary of Novartis AG, from January 1997 to May 1999. In 1999, Mr. Watson founded Pittencrieff Glen Associates, a private management consulting company. In addition to BioMimetic, he has served as the chairman of OraSure Technologies Inc. since March 2003 and as a director since April 2002. He has served as the chairman of Javelin Pharmaceuticals, Inc. since June 2003 and as a director since March 2001. He has served as a director of Dendreon Corporation since March 2000 and Genta Inc. since April 2002. Mr. Watson holds an M.A. degree in pure mathematics from Churchill College, Cambridge University, and is a member of the Chartered Institute of Management Accountants.

Organization Position Status
BioMimetic Therapeutics, Inc. Director, Chair Nominating and Governance Committee Current
Innovative Drug Delivery Systems, Inc. Chairman Current
BioMimetic Therapeutics, Inc. Director Current
BASF Catalysts LLC Director Current
Dendreon Corporation Director Current
Novartis AG Chief Executive Officer Former
Novartis AG President Former
Pittencrieff Glen Associates Founder Former
Sandoz Former
OraSure Technologies, Inc. Chairman Former
Innovative Drug Delivery Systems, Inc. Director Former
OraSure Technologies, Inc. Director Former
Cambridge University M.A. Degree In Pure Mathematics Former

Jim Murphy has been a director since September 2005. Mr. Murphy recently joined NMS Labs as Vice President, Finance. Prior to NMS, he served as Senior Vice President, Finance and Administration, and as Chief Financial Officer, of Immunicon Corporation since September 2000. From April 1999 to September 2000, Mr. Murphy served as Immunicon's Vice President, Finance and Administration. From April 1998 to April 1999, he was a consultant providing financial services to various venture-backed health care companies. From March 1996 to April 1998, Mr. Murphy was Vice President, Finance and Administration, and Chief Financial Officer of Apollon, Inc., a biotechnology company engaged in the development of DNA-based vaccines. From 1988 to 1995 Mr. Murphy served as Vice President, Chief Financial Officer and as a director of Infopage, Inc., a publicly-held radio beeper company that operated throughout the US. From 1987 to 1988, Mr. Murphy was Corporate Controller and Treasurer of American Cellular Network Corporation, a publicly-traded company that operated cellular telephone systems in New Jersey and Delaware. He holds a B.S. in Accounting, cum laude, from Villanova University, and is a certified public accountant.

Organization Position Status
Nms Labs Vice President of Finance Current
BioMimetic Therapeutics, Inc. Director, Chair Audit Committee Current
BioMimetic Therapeutics, Inc. Director Current
Immunicon Corporation Chief Financial Officer Former
Immunicon Corporation Vice President, Finance and Administration Former
Infopage Corporation Director Former
Villanova University B.S. In Accounting Former

Jim Murphy has been a director since September 2005. Mr. Murphy recently joined NMS Labs as Vice President, Finance. Prior to NMS, he served as Senior Vice President, Finance and Administration, and as Chief Financial Officer, of Immunicon Corporation since September 2000. From April 1999 to September 2000, Mr. Murphy served as Immunicon's Vice President, Finance and Administration. From April 1998 to April 1999, he was a consultant providing financial services to various venture-backed health care companies. From March 1996 to April 1998, Mr. Murphy was Vice President, Finance and Administration, and Chief Financial Officer of Apollon, Inc., a biotechnology company engaged in the development of DNA-based vaccines. From 1988 to 1995 Mr. Murphy served as Vice President, Chief Financial Officer and as a director of Infopage, Inc., a publicly-held radio beeper company that operated throughout the US. From 1987 to 1988, Mr. Murphy was Corporate Controller and Treasurer of American Cellular Network Corporation, a publicly-traded company that operated cellular telephone systems in New Jersey and Delaware. He holds a B.S. in Accounting, cum laude, from Villanova University, and is a certified public accountant.

Organization Position Status
Nms Labs Vice President of Finance Current
BioMimetic Therapeutics, Inc. Director, Chair Audit Committee Current
BioMimetic Therapeutics, Inc. Board of Directors Current
Immunicon Corporation Chief Financial Officer Former
Immunicon Corporation Senior Vice President, Finance and Administration Former
Immunicon Corporation Vice President, Finance and Administration Former

Organization Position Status
BioMimetic Therapeutics, Inc. Assoc Director, Corp Comm Current
BioMimetic Therapeutics, Inc. Manager Corporate Communications Former

Larry W. Papasan is the retired President of the Orthopaedic Division in Memphis, TN for Smith and Nephew. He serves on various boards, including Plough Foundation, University of Memphis Board of Visitors, and the LeBonheur Foundation.

Organization Position Status
Smith & Nephew, Inc. President Current
BioMimetic Therapeutics, Inc. Director and Chairman Current
Triumph Bank Board of Directors Current
Axiomed Spine Corporation Director Current
Ssr Engineering, Inc. Director Current
Mimedx, Inc. Director Current
Visitors Board of Directors Current
Smith & Nephew, Inc. Director Current
Smith & Nephew plc Director Former
BioMimetic Therapeutics, Inc. Board of Directors Former

Organization Position Status
BioMimetic Therapeutics, Inc. Assoc Director, Statistics Current

Earl Douglas, Esq. joined BioMimetic in May 2005 as General Counsel. Mr. Douglas has been a practicing attorney for almost 20 years and has a strong background in intellectual property law. Mr. Douglas served as Vice President and General Counsel of Spinal Dynamics Corporation from December 2001 to December 2002 and as Chief Patent Counsel from October 2000 to December 2001. Mr. Douglas was an intellectual property attorney for Smith & Nephew, Inc. from July 1995 to October 2000. Mr. Douglas received his J.D. from Columbia University and his B.S. in chemical engineering from the Massachusetts Institute of Technology.

Organization Position Status
BioMimetic Therapeutics, Inc. General Counsel Current
Smith & Nephew, Inc. Intellectual Property Attorney Former
Smith & Nephew plc Former
Columbia University J.D. Former
Massachusetts Institute of Technology B.S. in chemical engineering Former

Organization Position Status
BioMimetic Therapeutics, Inc. Professor Current
BioMimetic Therapeutics, Inc. Professor and Vice Chairman, Department of Orthopedics Current
Case Western Reserve University Professor of Biology Former

Organization Position Status
BioMimetic Therapeutics, Inc. Professor of Biological Sciences Current
BioMimetic Therapeutics, Inc. Board of Directors Current

Organization Position Status
BioMimetic Therapeutics, Inc. Professor of Orthopedic Surgery Current
BioMimetic Therapeutics, Inc. Board of Directors Current

Organization Position Status
BioMimetic Therapeutics, Inc. Professor of Neurosurgery, University of Tennessee Current
BioMimetic Therapeutics, Inc. Board of Directors Current

Organization Position Status
BioMimetic Therapeutics, Inc. Associate Clinical Professor of Periodontology Current
BioMimetic Therapeutics, Inc. Board of Directors Current

Dr. Gary Friedlaender has been a director of BioMimetic's board of directors since September 2006. Dr. Friedlaender is Chief of the Department of Orthopaedics and Rehabilitation at Yale New Haven Hospital and Professor of Orthopaedics and Rehabilitation at the Yale University School of Medicine. After earning his medical degree at the University of Michigan Medical School in Ann Arbor, Dr. Friedlaender completed his general surgery internship and residency at the University of Michigan Medical Center, and his orthopaedic residency at the Yale – New Haven Hospital and Newington Children's Hospital in Newington, Conn. He then completed a fellowship in musculoskeletal oncology at Massachusetts General Hospital in Boston. During active duty in the U.S. Navy, he was Director of the Naval Medical Research Institute's Tissue Bank Division in Bethesda, Md., and has since served on various medical advisory committees for the National Institutes of Health. Dr. Friedlaender has received several research grants and written numerous articles related to orthopedic reconstruction and bone grafting.

Organization Position Status
Yale-New Haven Hospital Chief of the Department Current
Yale University School of Medicine Professor Current
Rehabilitation, LLC Chair Current
BioMimetic Therapeutics, Inc. Chairman of Biomimetic's Orthopedic Sab Current
BioMimetic Therapeutics, Inc. Board of Directors Current
Carnegie Mellon University Director, Bone Tissue Engineering Center Former
Massachusetts General Hospital Director Tissue Bank Division Former
University of Michigan Medical School M.D. Former
University of Michigan Medical School Degree Former

Organization Position Status
Nms Labs Vice President of Finance Current
BioMimetic Therapeutics, Inc. Chair Current
BioMimetic Therapeutics, Inc. Director Current
Immunicon Corporation Chief Financial Officer Former
Immunicon Corporation Senior Vice President, Finance and Administration Former
Immunicon Corporation Vice President, Finance and Administration Former
Infopage Corporation Director Former
Villanova University B.S. In Accounting Former

Organization Position Status
BioMimetic Therapeutics, Inc. Professor and Chairman, Department of Orthopedics Current

Organization Position Status
BioMimetic Therapeutics, Inc. Board of Directors Current
Jefferson Medical College of Thomas Jefferson University Professor of Orthopedic Surgery Former

Organization Position Status
Anesiva Inc. Founder Current
InterWest Partners Partner Current
Interwest, Inc. Partner In the Menlo Park Vc Firm Interwest Partners Current
Biotechnology, Inc. Instructor Current
KAI Pharmaceuticals, Inc. Board Member Current
Applied Genetic Technologies Corporation Board Observer Current
Kai Pharmaceuticals, Inc Board of Directors Current
BioMimetic Therapeutics, Inc. Member of Biomimetic's Board of Directors Current
TransOral Pharmaceuticals, Inc. Board of Directors Current
BioMimetic Pharmaceuticals Board of Directors Current
Quatrx Pharmaceuticals Co Board of Directors Current
Technology Vision Group LLC Board of Directors Current
Xenon Pharmaceuticals Inc Board of Directors Current
Anesiva Inc. Board of Directors Current
Follica Inc. Board of Directors Current
Xenon Corp. Director Current
Salmedix, Inc. Board of Directors Current
Macrogenics, Inc. Board of Directors Current
Avera Inc Director Current
Genentech, Inc. Business Development Former
L.E.K. Consulting LLC Strategy Development Former
HiTech Equipment Former
Quatrx Pharmaceuticals Co Investor Former
KAI Pharmaceuticals, Inc. Investor Former
BioMimetic Pharmaceuticals Investor Former
TransOral Pharmaceuticals, Inc. Investor Former
Kellogg School of Management at Northwestern University M.B.A Former
Dartmouth College Bachelor's Degree Former

Douglas G. Watson is the founder of Pittencrieff Glen Associates, which was established in June, 1999. Prior to this, he was President and Chief Executive Officer of Novartis Corporation, the US subsidiary of Novartis A.G. Mr. Watson's career spanned 33 years with Geigy / Ciba-Geigy / Novartis. He joined Geigy (UK) Ltd in 1966, working first in Operations Research and then in Corporate Planning. Following the Ciba-Geigy merger, he spent one year in Basel , Switzerland as the UK representative to an international integration team. He returned to the UK in 1973 as accounting development and investment appraisal manager, and subsequently headquarters management accountant. In 1978, Doug returned to Basel as personal assistant to the Chairman of the Executive Committee. In 1981, he joined the US Pharmaceuticals Division as senior vice president of planning and business development, and a member of the Pharmaceuticals Management Committee. From 1986, he was President of Ciba Pharmaceuticals Division until 1996, when he was appointed President & CEO of Ciba-Geigy Corporation. During this ten year period, Mr. Watson was an active member of the Pharmaceutical Research & Manufacturers Association (PhRMA) board in Washington , DC . Mr. Watson became President & CEO of Novartis Corporation in 1997 when Ciba-Geigy & Sandoz merged. Mr Watson elected to take early retirement from Novartis in May, 1999. Mr. Watson, in addition, is Chairman of the board of OraSure Technologies Inc., and serves as a member of the board of directors for Engelhard Corporation, Genta Inc., Dendreon Corporation, BZL Biologics Inc., BioMimetic Pharmaceuticals Inc., BioElectronics Inc., InforMedix, Inc., and Innovative Drug Delivery Systems Inc. Prior board memberships include Novartis Corporation, Summit Bank Corporation, Principia Pharmaceuticals Inc., and ValiGen N.V. He has been a supporter of America 's Promise since its inception, and is chairman of the Freedom House Foundation, a non-profit organisation which treats adult men & women recovering from alcohol and drug addiction. He is a member of the Board of Directors of the American Liver Foundation, and on the President's Advisory Council of Drew University . Born near Pittencrieff Glen in the city of Dunfermline, Scotland, Mr. Watson holds an MA degree in pure mathematics from Churchill College, Cambridge University, and is a member of the Chartered Institute of Management Accountants.

Organization Position Status
Pittencrieff Glen Associates CEO Current
Informedix, Inc. Founder of Pittencrieff Glen Associates Current
Histofreezer Chairman of the Board, Orasure Technologies, Inc. Founder, Pittencrieff Glen Associates Current
Freedom House Foundation, Inc. Chairman Current
OraSure Technologies, Inc. Chairman of the Board Current
The Hepatitis C Support Project Board of Directors Current
American Liver Foundation Board of Directors Current
Innovative Drug Delivery Systems, Inc. Board of Directors Current
Epitope, Inc. Board of Directors Current
Informedix, Inc. Board of Directors Current
Genta Incorporated Board of Directors Current
BASF Catalysts LLC Board of Directors Current
BioMimetic Therapeutics, Inc. Board of Directors Current
Drew University Board of Directors Current
03.Tilt Board of Directors Current
OraSure Technologies, Inc. Member of The Board Current
Dendreon Corporation Board of Directors Current
Fleet Bank Member Current
Drew University Member Current
The Hepatitis C Support Project Committee Member Current
Epitope, Inc. Committee Member Current
Novartis AG Chief Executive Officer Former
The Hepatitis C Support Project Chairman of the Board, Orasure Technologies, Inc. Founder, Pittencrieff Glen Associates Former
Pittencrieff Glen Associates Founder Former
Innovative Drug Delivery Systems, Inc. Chairman Former
Cambridge University M.A. In Mathematics Former

Organization Position Status
BioMimetic Therapeutics, Inc. Board of Directors Current

Organization Position Status
BioMimetic Therapeutics, Inc. Board of Directors Current
Harvard School of Dental Medicine Director of Continuing Dental Education Former
Carnegie Mellon University Director, Bone Tissue Engineering Center Former
State University of New York at Buffalo Director of Science Former
Therapeutics Incorporated Editor Former

Organization Position Status
BioMimetic Therapeutics, Inc. Board of Directors Current

Organization Position Status
BioMimetic Therapeutics, Inc. Board of Directors Current

Organization Position Status
BioMimetic Therapeutics, Inc. Board of Directors Current

Executive News

  • Steven Holtzman Joins Satori Pharmaceuticals' Board of Directors

    Globe Investor - 9/03/09 - View Story

  • BioMimetic Therapeutics Reports 2009 Second Quarter Earnings Results

    Pharma Live - 8/11/09 - View Story

  • BioMimetic narrows loss in 2Q

    Biz Journals - 8/10/09 - View Story

  • BioMimetic Therapeutics Reports 2009 Second Quarter Earnings Results

    Business Wire - 8/10/09 - View Story

  • BioMimetic narrows loss in 2Q

    Nashville Business Journal - 8/10/09 - View Story

  • News and FDA Updates for BioMimetic (NASDAQ:BMTI), Neurogen (NASDAQ:NRGN), BioSante (NASDAQ:BPAX)

    Los Angeles Chronicle - 8/08/09 - View Story

  • BioMimetic Therapeutics, Inc. (BMTI) to Present at the Canaccord Adams Global Growth Conference

    BioSpace - 8/07/09 - View Story

  • BioMimetic Therapeutics, Inc. to Present at the Canaccord Adams Global Growth Conference

    Business Wire - 8/07/09 - View Story

advertisement
     BMTI $11.25 +0.07 (0.63% )
Average Volume 227,924
Shares Outstanding 21.79M
Market Cap 245.2M
Year High 15.81
Year Low 6.07
Earnings Per Share -1.76
P/E Ratio -6.39
Dividend N/A
Yield N/A
advertisement
Click Here